Vanqua Bio is a biopharmaceutical company focused on developing therapies targeting glucocerebrosidase (GCase) to treat Parkinson’s disease and Dementia with Lewy Bodies, utilizing insights into neuronal cell pathways and specialized assays. The company addresses the unmet medical need for effective treatments in neurodegenerative diseases, including Alzheimer’s, by targeting the overactivation of the innate immune system.
Funding
$149M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Parkinson's disease, Dementia with Lewy Bodies, and Alzheimer's disease lack effective treatments, creating a significant unmet medical need. These diseases often involve neuronal cell dysfunction and overactivation of the innate immune system.
Solution
Vanqua Bio is a biopharmaceutical company developing next-generation medicines for neurodegenerative diseases. Their approach combines insights into neuronal cell pathways with advanced assays to discover and develop therapies. Vanqua Bio's lead program targets glucocerebrosidase (GCase) for the treatment of Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). Additional programs address the overactivation of the innate immune system in central and peripheral disorders, including Alzheimer’s disease.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Parkinson's disease, Dementia with Lewy Bodies, and Alzheimer's disease, as well as the healthcare providers who treat them.
Features
- Focus on discovering and developing next-generation medicines for neurodegenerative diseases.
- Lead program targeting glucocerebrosidase (GCase) for Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB).
- Additional programs addressing overactivation of the innate immune system in Alzheimer’s disease and other disorders.
- Utilizes advanced insights into critical neuronal cell pathways.
- Employs cutting-edge assays to advance needed therapies.